S
Stockadora

Recent Annual Reports

Browse the latest SEC filings with AI-powered analysis. Get insights into corporate performance, financial trends, and business developments.

📊 4797 Reports
🤖 AI Analyzed
Recent
📄 Page 258 of 400
TIPTREE INC.
10-K March 9, 2026

Key Highlights

  • Diversified holding company with strong focus on insurance through its Fortegra ...
  • Achieved consolidated revenue growth and improved net income in 2023, primarily ...
  • Maintains a strong financial position with adequate liquidity and a manageable d...
Read Analysis
🤖 AI Generated
AMERICAN COASTAL INSURANCE Corp
10-K March 9, 2026

Key Highlights

  • Strategic divestiture of Interboro and UPC Insurance segments, expected to impro...
  • Strong financial performance for continuing operations in FY2023: Net Sales Reve...
  • Robust catastrophe reinsurance program providing $1.5 billion in coverage above ...
Read Analysis
🤖 AI Generated
LendingTree, Inc.
10-K March 9, 2026

Key Highlights

  • Operates as a leading online marketplace connecting consumers with a broad netwo...
  • Achieved positive operating cash flow of $35 million in FY 2023 despite a net lo...
  • Implemented significant strategic restructuring and closed non-core Ovation busi...
Read Analysis
🤖 AI Generated
ZEVRA THERAPEUTICS, INC.
10-K March 9, 2026

Key Highlights

  • Successfully completed patient enrollment for the pivotal Phase 3 trial of Arimo...
  • Secured Orphan Drug Designation and Fast Track designation from the FDA for ZVRA...
  • Reported $5.2 million in revenue for FY 2025, a 15% increase year-over-year, ind...
Read Analysis
🤖 AI Generated
Cartesian Therapeutics, Inc.
10-K March 9, 2026

Key Highlights

  • Expanded licensing agreement with Swedish Orphan Biovitrum AB (SOBI), validating...
  • Announced positive preliminary Phase 1/2 data for its lead candidate, ABC-001, i...
  • Successfully completed a Securities Purchase Agreement, raising additional capit...
Read Analysis
🤖 AI Generated
Eagle Bancorp Montana, Inc.
10-K March 9, 2026

Key Highlights

  • Healthy loan and deposit growth (6% and 4% respectively) despite a dynamic envir...
  • Strong asset quality with stable and low substandard loans and delinquencies, in...
  • Significant investment in Employee Stock Ownership Plan (ESOP) shares, aligning ...
Read Analysis
🤖 AI Generated
RBB Bancorp
10-K March 9, 2026

Key Highlights

  • Substantial increase in other operating income, skyrocketing over 118,000% to $4...
  • Reduction in shares outstanding by 3.4% from 17.7 million to 17.1 million, poten...
  • Robust cybersecurity and IT oversight framework, featuring a dedicated IT Commit...
Read Analysis
🤖 AI Generated
Coherus Oncology, Inc.
10-K March 9, 2026

Key Highlights

  • Coherus has strategically transformed into an oncology-focused biopharmaceutical...
  • The company generates revenue from key oncology products like Loqtorzi and manag...
  • A public offering in February 2026 provided critical additional capital to fund ...
Read Analysis
🤖 AI Generated
Amplify Energy Corp.
10-K March 9, 2026

Key Highlights

  • Strategic divestiture of non-core assets generated $70 million, used to reduce d...
  • Management is focused on streamlining operations, maximizing cash flow from exis...
  • Maintained a moderate leverage position with a debt-to-Adjusted EBITDA ratio of ...
Read Analysis
🤖 AI Generated
908 Devices Inc.
10-K March 9, 2026

Key Highlights

  • Achieved 15% year-over-year revenue growth to $85 million in FY2025.
  • Strategically divested 'Desktop Portfolio' to sharpen focus on core, high-growth...
  • Completed key acquisitions of RedWave Technology and Kaf Manufacturing to expand...
Read Analysis
🤖 AI Generated
Greenbacker Renewable Energy Co LLC
10-K March 9, 2026

Key Highlights

  • Greenbacker invests in, owns, and manages a diverse portfolio of renewable energ...
  • Revenue is primarily generated from electricity sales, Renewable Energy Credits ...
  • The company actively optimizes its portfolio through strategic divestitures (e.g...
Read Analysis
🤖 AI Generated
Corbus Pharmaceuticals Holdings, Inc.
10-K March 9, 2026

Key Highlights

  • Advancing two promising drug candidates: CRB-701 (oncology, Phase 1/2) and CRB-9...
  • Strategic shift to oncology solidified by the acquisition of CRB-701 rights in F...
  • Focused on addressing major unmet medical needs in high-potential therapeutic ar...
Read Analysis
🤖 AI Generated

Stay Informed with AI Analysis

Get comprehensive insights from annual reports with our AI-powered analysis. Track corporate performance, financial trends, and strategic developments.

Back to Homepage